One-year anniversary surprise: 46brooklyn receives tax-exempt non-profit status!

One-year anniversary surprise: 46brooklyn receives tax-exempt non-profit status!

Today, we are pleased to announce a more formalized organizational structure for 46brooklyn. This month, we received word from the IRS that 46brooklyn Research is now officially recognized as a 501(c)(3) Public Charity. As a tax-exempt non-profit organization, our main goal remains the same: to improve the accessibility and usability of U.S. drug pricing data. Our hope is that better awareness and education will help improve the accountability of our prescription drug supply chain and, in time, lead to the much-needed simplification of how drugs are priced.

What’s happening to generic drug prices? July 2019 NADAC Survey Update

What’s happening to generic drug prices? July 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw a lot of price increases this past month, and an overall decrease in annualized spending, after a couple months of concerning trends. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart.

Generic Lyrica launches at 97% discount to brand version

Generic Lyrica launches at 97% discount to brand version

Last week, the FDA dropped the big news that they had given the greenlight for generic manufacturers to officially enter the market to begin competing with Pfizer's blockbuster nerve pain medication, Lyrica. Not only was Lyrica going generic, but a whopping 10 manufacturers were approved to immediately begin releasing copycat versions into the prescription drug supply chain. With all the pricing criticism that Pfizer faced in years past over the drug, we knew that this would be a big moment for those who were unhappy with the brand-version's price. And we knew that with 10 different generic manufacturers, the price would likely drop pretty quickly. So, now that the generic has officially hit pharmacy shelves, we called some pharmacies to see just how low the price had gone, and we were stunned by the numbers.

New dashboard shows wild drug pricing variability in Medicare Part D

New dashboard shows wild drug pricing variability in Medicare Part D

It’s the middle of July. A time of year for pool parties, barbecues, campfires. and generally sweating your butt off. It’s a relaxing time of year for the majority of us. But what about the ski bums out there? It’s a long six months (five if you are lucky) until the first big dump of the year. At 46brooklyn, we sympathize with impatiently waiting for things – except rather than waiting to shred the gnar, we’ve been anxiously waiting to shred through Medicare Part D drug pricing data. Good news, drug pricing enthusiasts; we have a big (data) dump for you! After months of work on our newest drug pricing tool, we are pleased to release the Medicare Part D Drug Pricing Ski Slope dashboard. In this viz, we give you the ability to select one of many drugs (brand and generic, oral solid and non-oral solid), and view the price set by thousands of Part D plans for your selected drug. For good measure, we added a line to show you the true market-based cost of the drug (based on NADAC), so you can see how frustratingly random Part D pricing is by different plans for the same drug.

46brooklyn releases "Do-It-Yourself" tutorial to facilitate crowd-sourcing of drug pricing research

46brooklyn releases "Do-It-Yourself" tutorial to facilitate crowd-sourcing of drug pricing research

Do you like to tinker with data? Do you broadly distrust anything you have not created yourself? Are you tired of the drug supply chain funding their own studies telling you how wonderful they are, without telling you exactly how they calculated their wonderfulness? Well, you’re in luck. 46brooklyn has released our first video that will teach you how to construct our wildly-popular Medicaid Drug Pricing Heat Map from scratch. Our hope is that this will inspire you to create your own tools to help answer your drug pricing questions, with the conviction that can only come from “building the house” with your own two hands!

What’s happening to generic drug prices? June 2019 NADAC Survey Update

What’s happening to generic drug prices? June 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” It looks like we saw a lot of price increases this past month, and an overall increase in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart and new year-over-year generic deflation tracker!

What’s happening to generic drug prices? May 2019 NADAC Survey Update

What’s happening to generic drug prices? May 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” It looks like we saw a lot of price increases this past month, and an overall increase in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated and upgraded NADAC Packed Bubble Chart!

Newly released CMS drug pricing data reveals continued generic drug pricing distortions

Newly released CMS drug pricing data reveals continued generic drug pricing distortions

Last week, we were met with a delightful surprise as we were perusing through the CMS website and discovered an out-of-the-blue drug pricing data update just begging to be downloaded. The hidden treasure was the freshly-updated CMS State Utilization database, which provides quarterly drug pricing data that shows what state Medicaid programs are spending on prescription drugs, providing an excellent window into the price-setting practices of the prescription drug supply chain. This most recent CMS data update ended up filling in most of the Q3 2018 divots and extended the 2018 data to include large portions of the fourth quarter. We have updated all of our dashboards that rely on this dataset, rolling all of them forward to Q4 2018. We couldn't resist sneaking an extended peak at the data, and while we will offer more in-depth analyses soon, we wanted to give some of our initial takeaways.

What’s happening to generic drug prices? April 2019 NADAC Survey Update

What’s happening to generic drug prices? April 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” It looks like we saw a lot of price decreases this past month, and and overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated and upgraded NADAC Packed Bubble Chart!

New Ohio drug pricing data from shows where PBMs and pharmacies make their money

New Ohio drug pricing data from shows where PBMs and pharmacies make their money

For the first time in our existence, CMS has released drug pricing data that overlaps with the date of our launch. As we ripped open the data and examined CMS’ gift, we found some major changes in the way that the state of Ohio reported their data – and it has revealed some eye-opening information about PBM and pharmacy margins on prescription drugs. Given all the drug pricing noise out of Ohio, and the federal heat on PBM “spread pricing,” we decided to do a deep dive into what’s happening in Ohio, and how its new data provides incredible clues to determine where the money flows within the drug supply chain.

New CMS Medicaid drug pricing data released with stunning findings

New CMS Medicaid drug pricing data released with stunning findings

Recently, CMS updated their State Utilization databases, which provides quarterly drug pricing data that shows what state Medicaid programs are spending on prescription drugs. While Medicaid is only one (large) component of prescription drug spending, its importance is less based upon its size than it is the amazing amount of transparency in the program, relative to other segments of the market. This most recent CMS data update ended up filling in most of the Q2 2018 potholes and extended the 2018 data to include large portions of the third quarter. We have updated all of our dashboards that rely on this dataset, rolling all of them forward to Q3 2018, and there are some stunning takeaways.

What’s happening to generic drug prices? March 2019 NADAC Survey Update

What’s happening to generic drug prices? March 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” It looks like we saw a lot of price increases this past month, but overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated and upgraded NADAC Packed Bubble Chart!

It's time to dig into Medicare Part D drug prices

It's time to dig into Medicare Part D drug prices

Over the last nine months we have sliced and diced generic drug pricing within Medicaid managed care to arrive at the conclusion that generic prices in Medicaid are subject to wild and seemingly arbitrary distortions. But the million dollar (or should we say $2 billion dollar) question is whether this problem is isolated to Medicaid, or if it is a broader issue plaguing Medicare Part D and Commercial plans as well? We now attempt to bring data into the fold to help answer this question. In this report, we embark on an in depth investigation into the pricing of the top 15 generic drugs in Medicare Part D - drugs that represented roughly a third of overall Part D generic spending in 2017. It turns out that the same arbitrary generic pricing behavior we have observed in Medicaid is alive and well within Part D.

Brand drug list prices remain largely in check so far in 2019

Brand drug list prices remain largely in check so far in 2019

With two months of solid data so far in 2019, according to CMS data, brand drug list prices appear to be largely under control when compared to previous years. While the data does not reflect true net costs, these are noteworthy trends regardless, and signs of the erosion of the much-maligned drug pricing “gross-to-net-bubble.” Check out this update for a breakdown of the price increases, as well as an update on the peculiar case of generic Prilosec spending.

What’s happening to generic drug prices? February 2019 NADAC Survey Update

What’s happening to generic drug prices? February 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” It looks like we saw some very unfortunate generic inflation this past month. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated and upgraded NADAC Packed Bubble Chart!

New dashboard launched to examine Medicaid markup galaxies

New dashboard launched to examine Medicaid markup galaxies

Looking to drill deeper into a state’s markup universe? Then our newest viz is for you. Medicaid Markup Galaxies separates each universe into three different groups (or celestially-speaking, “galaxies”). We call them the High-Cost, In-Range, and Low-Cost galaxies. The goal in doing so is to better quantify the nature of generic pricing distortions within state Medicaid programs. Additionally in today’s update, we put a bow on January’s brand drug price increases. See how 2019 is shaping up.

What’s happening to generic drug prices? January 2019 NADAC Survey Update

What’s happening to generic drug prices? January 2019 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” On a positive note, it looks like there was a substantial amount of generic deflation in the aggregate. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated and upgraded NADAC Packed Bubble Chart!

New dashboard launched to track brand-drug price changes

New dashboard launched to track brand-drug price changes

The start of each new year brings a lot of “new-ness,” including a new round of price increases on brand-name drugs. This year has been no exception, and the media has been all over the subject. Unfortunately, we’ve found it difficult to figure out the “so what?” behind all of these price increases. On one hand, we are being told that the pharmaceutical manufacturers are back to “business as usual,” while on the other we are being told that the number of price increases are down meaningfully from last year. Which one is it? This felt like an opportunity to inject a healthy dose of facts into this discussion. So we set out to build a dashboard, 46brooklyn’s Brand Drug Price Change Box Score, that lets you visualize all brand-name manufacturer list price changes that are publicly-reported each week, drill down to the manufacturer and drug level, strength level, and compare and contrast different periods.

Slicing up the Pie: New dashboard launched to track drugmaker market share

Slicing up the Pie: New dashboard launched to track drugmaker market share

If you’re trying to discover reasons for why drug prices go up or down, one of the best things to look at is supply and demand. A new federal antitrust lawsuit alleges that several generic drugmakers were colluding in an effort to protect market share and raise prices. To get a better sense of what was happening in the market at the time the alleged collusion took place, it helps to track a drug’s market share over time. Using Medicaid utilization data and other public datasets, we have now launched a new dashboard to provide a crumb trail for those looking to determine the market distribution of drug manufacturers as prices fluctuate.

What’s happening to generic drug prices? December 2018 NADAC Survey Update

What’s happening to generic drug prices? December 2018 NADAC Survey Update

It’s NADAC survey results week, which means it’s time for our fifth installment of “what happened to generic drug prices last month.” On a positive note, it looks like there was a bit of net deflation. But overall it was a less than stellar month for generic deflation - it was the first month (since we started this monthly review) where we saw more generic drug price increases then decreases. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart!